KMT2Ar clinical trials at UCSF

1 research study open to eligible people

KMT2Ar is a gene fusion that can drive leukemia. UCSF is studying drug combos for patients with relapsed or treatment-resistant acute myeloid leukemia. One study tests ziftomenib with standard therapy to look at safety and antileukemic response.

Showing trials for

  • Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    open to eligible people ages 18 years and up

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    San Francisco, California and other locations

Our lead scientists for KMT2Ar research studies include .

Last updated: